Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs).



Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.



Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D). Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D). In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg. Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs.



The early response criterion was clinically useful to identify individuals who would achieve clinically meaningful weight loss at 56 weeks.
Scripps Clinic, La Jolla, California, USA. fujioka.ken@scrippshealth.org.
Ken
K
Fujioka
Department of Psychiatry and Behavioral Sciences, Weight Management Center, Medical University of South Carolina, Charleston, South Carolina, USA.
Patrick M
PM
O'Neil
Department of Health Sciences, Diabetes Research Centre, University of Leicester, Leicester, UK.
Melanie
M
Davies
Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Frank
F
Greenway
Departments of Medicine, Biochemistry and Molecular Biology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
David
D
C W Lau
Novo Nordisk A/S, Søborg, Denmark.
Birgitte
B
Claudius
Novo Nordisk A/S, Søborg, Denmark.
Trine Vang
TV
Skjøth
Novo Nordisk A/S, Søborg, Denmark.
Christine
C
Bjørn Jensen
Department of Obesity and Endocrinology, University of Liverpool, Liverpool, UK.
John
J
P H Wilding
D000328:Adult; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D015415:Biomarkers / Q000097:blood*; D015992:Body Mass Index; D001835:Body Weight; D002319:Cardiovascular System / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D023381:Endpoint Determination; D015444:Exercise; D005260:Female; D006801:Humans; D000069450:Liraglutide / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood; D011236:Prediabetic State / Q000097:blood; D011788:Quality of Life; D012137:Respiratory System / Q000187:drug effects; D012307:Risk Factors; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects*
D019440:Anti-Obesity Agents; D015415:Biomarkers; D000069450:Liraglutide